1. Home
  2. NOW vs VRTX Comparison

NOW vs VRTX Comparison

Compare NOW & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ServiceNow Inc.

NOW

ServiceNow Inc.

N/A

Current Price

$116.78

Market Cap

107.2B

Sector

Technology

ML Signal

N/A

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$499.96

Market Cap

115.7B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
NOW
VRTX
Founded
2004
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
EDP Services
Sector
Technology
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
107.2B
115.7B
IPO Year
2012
2006

Fundamental Metrics

Financial Performance
Metric
NOW
VRTX
Price
$116.78
$499.96
Analyst Decision
Strong Buy
Buy
Analyst Count
31
27
Target Price
$202.70
$526.79
AVG Volume (30 Days)
17.0M
1.3M
Earning Date
04-29-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
836.54
EPS
1.67
15.32
Revenue
$1,933,026,000.00
$2,488,652,000.00
Revenue This Year
$21.52
$10.79
Revenue Next Year
$18.41
$10.14
P/E Ratio
$74.28
$29.80
Revenue Growth
39.02
46.20
52 Week Low
$98.00
$362.50
52 Week High
$1,057.39
$519.68

Technical Indicators

Market Signals
Indicator
NOW
VRTX
Relative Strength Index (RSI) 40.97 59.25
Support Level $98.59 $426.38
Resistance Level $136.63 $503.88
Average True Range (ATR) 4.67 15.97
MACD 7.30 0.48
Stochastic Oscillator 68.68 81.77

Price Performance

Historical Comparison
NOW
VRTX

About NOW ServiceNow Inc.

ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: